[PDF] Top 20 Immunotherapy for lethal prostate cancer.

... Preliminary results from the KEYNOTE-199 phase II trial evaluating the efficacy of pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC) were presented by de Bono et al. 4 at the 2018 ... See full document

... validated prostate cancer out- ...for prostate can- ...of lethal events, especially limiting our statistical power in our subgroup analyses; therefore, these results should be interpreted ... See full document

... in cancer appears to be dependent on tumor type and subunit (25, ...The Cancer Genome Atlas (TCGA) and other data sets, we found no statistical evidence for a mutually exclusive deletion pattern between ... See full document

... or lethal prostate cancer during the study period were the primary ...Total prostate cancer incidence was studied as a secondary ...reports. Prostate cancer was ... See full document

... TRAMP-C2 prostate tumor cells ...of prostate tumors to replenish their suppressive myeloid ...of prostate tumors to recruit and suppressively polarize new myeloid ... See full document

... population diversity, which is estimated using the Shannon Index. n=36 G) CHD1 protein level in HSPC and CRPC biopsies. Blue indicates protein loss. Grey indicates protein expr[r] ... See full document

... advanced prostate cancer have progressed to Phase II or Phase III clinical ...(GM-CSF immunotherapy for cancer), which involves intradermal administration of irradiated, allogeneic tumor cells ... See full document

... are involved in at least part of the effect. It is well documented that tissue-impairing agents (such as cyclophosphamide or TBI) induce the production and secretion of SDF-1 as part of the tissue- regenerative process ... See full document

... diversity using a multiplex polymerase chain reaction assay that amplified rearranged B-cell receptors and T-cell recep- tors in pretreatment and post-treatment peripheral blood mononuclear cells from 46 patients with ... See full document

... adoptive immunotherapy has received great attention and made great ...tumor immunotherapy, significantly different from traditional T ...of prostate cancer, and discuss the promise of the ... See full document

... from cancer patients are identical to those observed with normal donors [33, ...of cancer patients fail to respond if they have advanced metastatic disease, are elderly, or have been treated with ... See full document

... castration-resistant prostate cancer; MDSC: Myeloid-derived suppressor cell; MTD: Maximum tolerated dose; MVA: Modified vaccinia Ankara; NK: Natural killer; NSCLC: Non-small cell lung cancer; PD-1: ... See full document

... As noted in previous studies, 5,7,13 we observed a striking upgrading of GS in a standardized review compared to the original reading. No patients were assigned a GS of 2 on standardized review and fewer than 1% received ... See full document

... of cancer vaccines is to use an antigen- containing vector (or the antigen itself) to activate an immune response against protein epitope/s expressed and displayed by tumor ... See full document

... surrounding prostate cancer overtreatment emphasize the critical need to delineate the molecular features associated with progression to lethal metastatic ...the lethal cell clone in a patient ... See full document

... The promise of cancer immunotherapy appears to be on the verge of delivering. Most of us in the urological com- munity have likely always been believers to some degree, given modest past successes in renal ... See full document

... of cancer immunotherapy with the goal to improve outcomes for people with ...of immunotherapy in the clinical setting and generate consensus ...The Prostate Cancer Im- munotherapy ... See full document

... Prostate cancer and chronic lymphocytic leukemia (CLL) are relatively common malignancies associated with advanced ...Although immunotherapy-based strategies are used to treat both, currently, there ... See full document

... The clinical trials with APC8015 to date indicate a moderate degree of immunological response that provides some therapeutic benefi t. The level of response, however, is not as robust in many patients, as might be hoped ... See full document

... castration-resistant prostate cancer (CRPC) and commercial production of inhibitors of adrenal sources of androgens and AR pathway inhibitors such as galeterone, abiraterone and enzalutamide ... See full document